<DOC>
	<DOCNO>NCT00386542</DOCNO>
	<brief_summary>This sequential phase I II , control , double-blinded study determine whether immune response suggest protection influenza safely induced young child two reduce dos one month apart 0.1 mL trivalent inactivate influenza vaccine ( INF ) administer intradermal ( ID ) route investigational ID spacer United States ( U.S. ) -licensed needle-free jet injector ( JI ) , compare two standard intramuscular ( IM ) 0.25 mL dos needle-syringe ( N-S ) age group . The locale develop country financial restraint use full-dose influenza vaccine would limit protection influenza pandemic threat , N-Ss pose danger drawback clinical use , Mantoux-type N-S ID injection difficult administer mass campaign .</brief_summary>
	<brief_title>Needle-free Jet Injection Reduced-dose , Intradermal , Influenza Vaccine &gt; = 6 &lt; 24-month-old Children</brief_title>
	<detailed_description>Randomized , observer-blinded , clinical pilot ( phase I ) trial safety , follow clinical ( phase II ) trial safety non-inferiority immune response standard route dose merge subject phase . Phase I - Influenza-vaccine naïve child ( n = 48 ) age &gt; = 6 &lt; 24 month randomize 1:1:1 ratio follow three study arm , receive two dos day 0 28 trivalent inactivate influenza ( INF ) vaccine ( Vaxigrip® , Sanofi Pasteur , Lyon , France ) leave thigh ( &lt; 12 month ) leave deltoid ( ≥ 12 month ) : - Group `` ID-JI-0.1 '' ( n = 16 ) - reduce 0.1 mL INF dose administer intradermally ( ID ) needle-free jet injector ( JI ) ( Biojector® 2000 subcutaneous syringe . 2 [ green color code ] , 2 cm investigational spacer , Bioject Medical Technologies , Inc. , Portland , OR , USA ) - Group `` IM-NS-0.1 '' ( n = 16 ) - reduce 0.1 mL INF dose administer intramuscularly ( IM ) needle-syringe ( NS ) ( via 22-25 gauge needle , minimum 25 mm/1-inch length ) - Group `` IM-NS-0.25 '' ( control ) ( n = 16 ) - full 0.25 mL INF dose administer intramuscularly ( IM ) needle-syringe ( NS ) ( 22-25 gauge needle , minimum 25 mm/1-inch length ) Phase II - Upon assessment safety profile phase I unblinded Data Safety Monitoring Board ( DSMB ) , approval additional 402 child recruit randomize ( 134 per group ) phase I . Total subject phase I II = 450 ( 150 three study arm ) . Adverse Event Diaries : Parents train complete diary form observe , measure , record solicit local reaction injection site systemic sign symptom child day 0 7 vaccination , plus unsolicited symptom , illness , medication day 0 28 . Followup : Return clinic visit schedule day 2 , 7 , 28 INF dose 1 , time diary card data record staff card collect day 28 . Upon receive dose 2 vaccine , patient schedule return study center 2 , 7 , 28 day afterwards . The procedure dose 1 regard diary card , telephone followup , home visit apply dose 2 . Upon return clinic day 28 dose 2 ( day 56 dose 1 ) , child receive unblinded , `` insurance '' , full-volume , 0.25 mL dose ( # 3 ) influenza vaccine NS IM , unless full-dose IM control group IM-NS-0.25 , case mock injection administer instead 3rd full dose beyond usual 2-dose series . All participant return 6 month third injection fourth `` bonus '' dose influenza vaccine ensure protection follow season . Serum Collection : Blood specimen measure serologic response collect three time , prior vaccination day 0 ( INF dose 1 ) , day 28 ( INF dose 2 ) , day 56 ( INF `` insurance '' dose 3 ) . Ethical oversight additional CDC IRB G ( 1 ) World Health Organization Research Ethics Review Committee , ( 2 ) Consejo Nacional de Bioética en Salud , ( 3 ) Fundación Dominicana de Infectología Comité de Etica/Investigaciones .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age &gt; = 6 &lt; 24 month ( reach 2nd birthday ) . Born fullterm ( ≥ 37 week ) , birth weight &gt; = 2.5 kg ( &gt; = 5 pound , 8 ounce ) History prior first attendance patient , sibling patient , seek routine immunization clinical care Hospital Infantíl Robert Reid Cabral ( HIRRC ) The parent ( ) legal guardian ( ) provide ( ) write informed consent agree ( ) bring infant back clinic visit schedule study Uptodate routine dose vaccine officially recommend patient 's age Dominican Republic prevent tuberculosis , polio , diphtheria , tetanus , pertussis , hepatitis B , Haemophilus influenzae B In good health , determine medical history physical examination collect accordance Case Report Form ( CRF ) , clinical judgment investigator . Infants WHOSE PARENT ( S ) /LEGAL GUARDIAN ( S ) : Are unable unwilling give write informed consent infant participate study Can contact telephone ( family 's neighbor 's ) necessary adverse event schedule followup return appointment miss Are unable complete diary adverse event ; unable measure record temperatures maximal diameter local reaction limb circumference ; difficulty understand write instruction ; factor indicate exclusion judgement study staff . INFANTS : Have fever ( parental report rectal temperature ≥ 38.5° C axillary ≥ 38.0° C ) currently within past 3 day , currently suffer acute chronic infectious disease ( include know HIV ) Have acute chronic infection require systemic antimicrobial therapy ( antibiotic antiviral ) prescribe treatment within past 21 day . This include underlying illness may limit response vaccination , receive intravenous immunoglobulin agammaglobulinemia , systemic steroid therapy . Are malnourish , define weight less two standard deviation median weight age Are allergic egg , history anaphylactic shock , asthma , urticaria , allergic reaction previous vaccination , allergy hypersensitivity component study vaccine Have ever previously receive influenza vaccine Have receive within prior 28 day , indication receive next 56 day , nonstudy vaccination investigational agent outside study Have know bleeding diathesis , condition prolong bleeding time Currently serious confirm suspected disease , metabolic , cardiac , autoimmune disease , diabetes Have history epilepsy seizure disorder , neurodevelopmental disorder autism Have genetic anomaly know cytogenic disorder ( e.g. , Down 's syndrome ) Have leukemia , lymphoma , cancer/neoplasm Have know suspect immune dysfunction , include HIV infection , receives ( ed ) immunosuppressive therapy , include systemic corticosteroid Have ever receive blood , blood product , parenteral preparation immunoglobulin Have serious disease ( e.g. , sign cardiac renal failure ) , include progressive neurologic disease Have condition , opinion investigator , may interfere evaluation objective study</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>vaccination</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>jet injection</keyword>
	<keyword>intradermal injection</keyword>
	<keyword>infancy</keyword>
	<keyword>child</keyword>
	<keyword>dose-sparing</keyword>
	<keyword>cutaneous vaccination</keyword>
	<keyword>Dominican Republic</keyword>
	<keyword>pandemic preparedness</keyword>
	<keyword>jet injector</keyword>
	<keyword>reduce dosage</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>reactogenicity</keyword>
	<keyword>safety</keyword>
	<keyword>needle-free</keyword>
	<keyword>immune response</keyword>
	<keyword>hemagglutination inhibition</keyword>
	<keyword>Infant</keyword>
</DOC>